Negative predictive value of 123I Ioflupane SPECT in movement disorders;Valor predictivo negativo del SPECT con Ioflupano 123I en los trastornos del movimiento

Revista Espanola de Medicina Nuclear

Volumn 28, Issue 1, 2009, Pages 2-5

  Serrano Vicente, J ^a   Garcia Bernardo L ^a   Duran Barquero C ^a   Constantino Silva, A ^a   Infante de la Torre, J R ^a   Dominguez Grande M L ^a   Rayo Madrid, J I ^a   Sanchez Sanchez R ^a   Duran Herrera C ^a  

^a Badajoz Servicio de Urgencias Complejo Universitario Hospitalario de Badajoz Badajoz Espana   (Spain)

Author keywords

Dopamine transporters; Ioflupane; Movement disorders; Parkinson; SPECT

Indexed keywords

IOFLUPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; IOFLUPANE; NORTROPANE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; ATROPHY; CLINICAL ARTICLE; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; ESSENTIAL TREMOR; FEMALE; FIBROMYALGIA; HUMAN; INTRACRANIAL HYPERTENSION; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PERIPHERAL NEUROPATHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR DISEASE; WRITER'S CRAMP; EVALUATION; MIDDLE AGED; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MOVEMENT DISORDERS; NEURODEGENERATIVE DISEASES; NORTROPANES; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 85047684715     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S1578-200X(09)70009-9     Document Type: Article

References (20)

1. Hughes A.J., Daniel S.E., and Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (2001) 1497-1499
2. Poewe W., and Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol 9 Suppl 3 (2002) 23-30
3. Jankovic J., Rajput A., McDermott M., and Perl D.P. The evolution of diagnosis in early Parkinson disease. Parkinson study Group. Arch Neurol 57 (2000) 369-372
4. Louis E.D., Levy G., Cote L.J., Mejia H., Fahn S., and Marder K. Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses. Mov Disord 17 (2002) 513-517
5. Weiner W.J. A differential diagnosis of Parkinsonism. Rev Neurol Dis 2 (2005) 124-131
6. Booij J., Tissingh G., Winogrodzka A., Boer G.J., Stoof J.C., Wolters E.C., et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 24 (1997) 68-71
7. Catafau A.M., Tolosa E., and DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19 (2004) 1175-1182
8. Catafau A.M., and Semih Dogan A. PET and SPECT of cerebral neurotransmission. Rev Esp Med Nucl 22 (2003) 109-121
9. García Vicente A.M., Vaamonde Cano J., Poblete García V.M., Rodado Marina S., Cortés Romera M., Ruiz Solís S., et al. Utility of dopamine transporter imaging (123-I Ioflupane SPECT) in the assessment of movement disorders. Rev Esp Med Nucl 23 (2004) 245-252
10. Benamer T.S., Patterson J., Grosset D.G., Booij J., de Bruin K., van Royen E., et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15 (2000) 503-510
11. Fahn S., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., et al. Levodopa and the progression of Parkinson's disease. New Engl J Med 351 (2004) 2498-2508
12. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
13. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
14. Benamer H.T., Patterson J., Wyper D.J., Hadley D.M., Macphee G.J., and Grosset D.G. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15 (2000) 692-698
15. Filippi L., Manni C., Pierantozzi M., Brusa L., Danieli R., Stanzione P., et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun 26 (2005) 421-426
16. Kemp P.M. Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia. Nucl Med Commun 26 (2005) 87-96
17. Ahlskog J.E., Uitti R.J., O'Connor M.K., Maraganore D.M., Matsumoto J.Y., Stark K.F., et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 14 (1999) 940-946
18. Marshall V., and Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18 (2003) 1415-1423
19. Marek K., Jennings D.L., and Seibyl J.P. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 64 Suppl 1 (2005) A274
20. Marshall V.L., Patterson J., Hadley D.M., Grosset K.A., and Grosset D.G. Two-year follow up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Comm 27 (2006) 933-937